​
​

NewAmsterdam Pharma Company (NAMS) Revenue & Revenue Breakdown

OverviewForecastFinancialsChart

NewAmsterdam Pharma Company Revenue Highlights

Latest Revenue (Y)

$14.09M

Latest Revenue (Q)

$2.13M

Main Segment (Y)

License Revenue

NewAmsterdam Pharma Company Revenue by Period

NewAmsterdam Pharma Company Revenue by Year

DateRevenueChange
2023-12-31$14.09M-85.55%
2022-12-31$97.50M100.00%
2021-12-31-100.00%
2020-12-31--

NewAmsterdam Pharma Company generated $14.09M in revenue during NA 2023, up -85.55% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

NewAmsterdam Pharma Company Revenue by Quarter

DateRevenueChange
2024-06-30$2.13M63.86%
2024-03-31$1.30M-18.58%
2023-12-31$1.59M-15.06%
2023-09-30$1.88M19.31%
2023-06-30$1.57M-80.22%
2023-03-31$7.96M515.29%
2022-12-31$1.29M-76.98%
2022-09-30$5.62M-87.98%
2022-06-30$46.75M-
2022-03-31$46.75M100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

NewAmsterdam Pharma Company generated $2.13M in revenue during Q2 2024, up 63.86% compared to the previous quarter, and up 26.74% compared to the same period a year ago.

NewAmsterdam Pharma Company Revenue Breakdown

NewAmsterdam Pharma Company Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22
License Revenue$97.50M

NewAmsterdam Pharma Company's latest annual revenue breakdown by segment (product or service), as of Dec 22: License Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 23
License Revenue$4.56M

NewAmsterdam Pharma Company's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License Revenue (100.00%).

NewAmsterdam Pharma Company Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRUSMerus$43.95M$11.77M
IVAInventiva$17.50M$15.58M
NAMSNewAmsterdam Pharma Company$14.09M$2.13M
JANXJanux Therapeutics$8.08M$8.90M
MOLNMolecular Partners$7.04M$2.74M
CRNXCrinetics Pharmaceuticals$4.01M-
PRTCPureTech Health$3.33M$178.57K
ANEBAnebulo Pharmaceuticals--
CGEMCullinan Oncology--
RZLTRezolute--
REPLReplimune Group--
CYTCyteir Therapeutics--
ELYMEliem Therapeutics--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
CMPXCompass Therapeutics--
PEPGPepGen--

NAMS Revenue FAQ

What is NewAmsterdam Pharma Company’s yearly revenue?

NewAmsterdam Pharma Company's yearly revenue for 2023 was $14.09M, representing a decrease of -85.55% compared to 2022. The company's yearly revenue for 2022 was $97.5M, representing an increase of 100.00% compared to 2021. NAMS's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

What is NewAmsterdam Pharma Company’s quarterly revenue?

NewAmsterdam Pharma Company's quarterly revenue for Q2 2024 was $2.13M, a 63.86% increase from the previous quarter (Q1 2024), and a 35.21% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.3M, a -18.58% decrease from the previous quarter (Q4 2023), and a -83.68% decrease year-over-year (Q1 2023). NAMS's quarterly revenue for Q4 2023 was $1.59M, a -15.06% decrease from the previous quarter (Q3 2023), and a 23.33% increase year-over-year (Q4 2022).

What is NewAmsterdam Pharma Company’s revenue growth rate?

NewAmsterdam Pharma Company's revenue growth rate for the last 3 years (2021-2023) was 0%

What are NewAmsterdam Pharma Company’s revenue streams?

NewAmsterdam Pharma Company's revenue streams in c 22 are License Revenue

What is NewAmsterdam Pharma Company’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of NewAmsterdam Pharma Company was License Revenue. This segment made a revenue of $97.5M, representing 100.00% of the company's total revenue.